IBRX
Immunitybio Inc
NASDAQ: IBRX · HEALTHCARE · BIOTECHNOLOGY
$6.96
+0.00% today
Updated 2026-04-29
Market cap
$7.19B
P/E ratio
—
P/S ratio
63.45x
EPS (TTM)
$-0.38
Dividend yield
—
52W range
$2 – $12
Volume
27.9M
Immunitybio Inc (IBRX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-668000.00 | $-5.35M | $-25.30M | $-38.59M | $-48.78M | $-63.38M | $-152.11M | $-171.72M | $-274.42M | $-337.51M | $-366.76M | $-391.24M | $-304.94M |
| Capital expenditures | $3000.00 | $299000.00 | $2.24M | $6.56M | $34.81M | $13.10M | $4.29M | $1.67M | $33.56M | $78.16M | $30.58M | $6.89M | $3.85M |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $884000.00 | $789000.00 | $211.22M | $73.85M | $37.00M | $2.04M | $3.42M | $2.19M | $57.18M | $40.18M | $49.16M | $34.43M | $36.81M |
| Free cash flow | $-671000.00 | $-5.65M | $-27.55M | $-45.15M | $-83.59M | $-76.48M | $-156.40M | $-173.39M | $-307.98M | $-415.67M | $-397.34M | $-398.12M | $-308.78M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | $2.28M | $4.44M | $334.44M | $616000.00 | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | $-4.07M | $146.14M | $-76.60M | — | — | — |